Topiramate added to usual treatment for persistent obsessive-compulsive symptoms
About this title
Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)
Read the official source — NCT00182520Researchers compared Topiramate and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Understand this study
What did researchers investigate?
Researchers compared Topiramate and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- HamiltonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 23
- Sponsor
- McMaster University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00182520
- Official title
Show the full official title
A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Hamilton
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Topiramate and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.
Who is behind this study?
The study sponsor is McMaster University, a university.
Did this study involve medication?
Yes. The study involved medication, including Topiramate and placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
